Stockwinners Market Radar for March 03, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:23 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Tesla (TSLA) CEO Elon Musk said via Twitter that, "Model Y unveil event on March 14 at LA Design Studio... Model Y, being an SUV, is about 10% bigger than Model 3, so will cost about 10% more & have slightly less range for same battery... Detailed specs & pricing will be provided, as well as test rides in Y." 2. China and the U.S. are in the final stage of completing a trade deal, with Beijing offering to lower tariffs and other restrictions on American farm, chemical, auto and other products and Washington considering removing most, if not all, sanctions levied against Chinese products since last year, The Wall Street Journal's Lingling Wei and Bob Davis reported. While hurdles remain, the talks have progressed to the extent that a formal agreement could be reached at a summit between President Trump and Chinese President Xi Jinping, probably around March 27, the publication added, citing people familiar with the matter. 3. Big Pharma has been struggling for years to produce drugs that are major breakthroughs in medicine and gene therapy may be "the promise land," offering potential for hundreds of genetic diseases, Andrew Bary wrote in this week's edition of Barron's. That promise, and its rich commercial potential, has led to a land grab among the drug giants, with the latest being Roche (RHHBY), which agreed to pay $4.8B for Spark Therapeutics (ONCE), following last year's acquisition of AveXis by Novartis (NVS), the report noted. Six publicly traded gene therapy-focused biotechs, and two whose treatments include gene therapy, offer investors a way to bet on the new genetic technology, namely as uniQure (QURE), Regenxbio (RGNX), Audentes Therapeutics (BOLD), Solid Biosciences (SLDB), MeiraGTx Holdings (MGTX), Voyager Therapeutics (VYGR), Sarepta Therapeutics (SRPT), the publication added. 4. Comcast (CMCSA; CMCSK) subsidiary Universal's "How to Train Your Dragon: The Hidden World" won the weekend box office with another $30M in its second weekend for a domestic total of $97.9M. Overseas, the movie earned $52M from 61 markets for a foreign cume of $277.7M and $375.4M globally. The sequel sports an audience grade of A and a 92% Rotten Tomatoes score. 5. AbbVie (ABBV), Broadcom (AVGO), SL Green Realty (SLG), Regions Financial (RF), Philips 66 (PSX), Marathon Petroleum (MPC), T. Rowe Price (TROW), PNC Financial (PNC), JPMorgan (JPM), Comerica (CMA), Gap (GPS), Lumentum's (LITE), and Ferrari (RACE) saw positive mentions in Barron's, while Kraft Heinz (KHC) and L Brands (LB) were mentioned cautiously.

16:41 EDT Box Office Battle: 'How to Train Your Dragon 3' wins weekend with another $30M - Comcast (CMCSA; CMCSK) subsidiary Universal's "How to Train Your Dragon: The Hidden World" won the weekend box office with another $30M in its second weekend for a domestic total of $97.9M. Overseas, the movie earned $52M from 61 markets for a foreign cume of $277.7M and $375.4M globally. The sequel sports an audience grade of A and a 92% Rotten Tomatoes score. BOX OFFICE RUNNERS-UP: Lionsgate's (LGF.A) "Tyler Perry's A Madea Family Funeral" placed number two, with $27M in its debut weekend. Behind it was Fox's (FOXA) "Alita: Battle Angel," earning another $7M for a domestic total of $72.2M. AT&T (T) subsidiary Warner Bros' "The Lego Movie 2: The Second Part" placed number 4 with $6.6M for a domestic tally of $91.7M and $152.8M worldwide. Rounding out the top five, Comcast subsidiary Universal's "Green Brook" grossed an estimated $4.7M for a North American total of $75.9M. Other publicly traded companies in filmmaking include Disney (DIS), Viacom (VIAB) and Sony (SNE).

12:32 EDT NHL Alumni, Canopy Growth team up to research concussions, cannabinoids - NHL Alumni Association, NEEKA Health Canada and Canopy Growth have announced a transformative clinical research partnership that will investigate the efficacy of cannabinoids as an integral part of a novel treatment for post-concussion neurological diseases in former NHL players. The study will undertake the rigorous science needed to establish the medicinal value of cannabis when combined with other proven treatments amongst this highly-afflicted group of elite athletes and potentially improve their ability to interact with family, friends and their communities. Approximately 100 former players will be enrolled in this randomized double-blind study. The study is expected to begin in summer 2019 and will take one year to complete.

12:25 EDT Principia Biopharma announces data from Phase 2 Pemphigus Vulgaris trial - Principia Biopharma announced Phase 2 clinical data from the Believe-PV study for PRN1008 as part of the Late-breaking Research: Clinical Trials program at the American Academy of Dermatology annual meeting in Washington D.C. PRN1008 is being developed for the potential treatment of pemphigus, including pemphigus vulgaris and pemphigus foliaceus. Confirming interim clinical results previously reported, the Phase 2 study reached the primary efficacy measurement of control of disease activity on low dose corticosteroids. The open-label Phase 2 study enrolled 27 patients with newly diagnosed and relapsed, mild to severe pemphigus. 24 patients were treated with oral PRN1008 and low dose corticosteroids for 12 weeks, with 12 weeks of follow-up. The primary endpoint was CDA at Week 4. Other secondary endpoints included complete remission rates and reduction in anti-desmoglein autoantibody levels. The study achieved the primary endpoint of CDA on low dose corticosteroids at 4 weeks in 54% of patients. The CDA results were generally consistent across all major subgroups; At Week 12, CDA occurred in 73% of patients; Of 24 patients who completed the study after 12 weeks of treatment, 17% achieved a complete response by Week 12 and 25% by Week 24; and PRN1008 was generally well-tolerated. The most frequently reported treatment-related adverse events were nausea, abdominal pain, and headache. There was one treatment-related serious adverse event in a patient with a localized patch of leg cellulitis, whose treatment with PRN1008 resumed after three days for a further eight weeks without event recurrence. The company has an ongoing global, randomized, double-blind, placebo-controlled, pivotal, Phase 3 clinical trial, the PEGASUS study, with planned enrollment of approximately 120 patients to evaluate PRN1008 versus placebo, using a background treatment of tapering doses of CS. PRN1008 has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of patients with PV and by the European Commission for treatment of patients with pemphigus. Principia has initiated a Phase 2 extension to the Believe-PV clinical trial by increasing the active treatment period from 12 to 24 weeks, with a post-treatment follow-up period of four weeks. The top-line results from the Phase 2 extension are anticipated in the fourth quarter of 2019.

12:18 EDT Biogen responds to CADTH recommendation regarding SPINRAZA coverage - Canadian Association of Drugs and Technologies in Health, or CADTH, has publicly released updated recommendations that could inform provincial jurisdictions' decisions on the public reimbursement of SPINRAZA, the first and only approved treatment shown to be effective in the treatment of Spinal Muscular Atrophy. The updated recommendation has been expanded to include patients with genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygote; are pre-symptomatic with two or three copies of SMN2, or have had disease duration of less than six months, two copies of SMN2, and symptom onset after the first week after birth and on or before seven months of age, or are 12 years of age or younger with symptom onset after six months of age, and never achieved the ability to walk independently; patient is not currently requiring permanent invasive ventilation. Biogen said in a statement that, "While the expanded CADTH recommendation will provide access to treatment for a larger subset of patients with SMA, it is disappointing that the clinical criteria in the recommendation continue to limit access to treatment for many patients with SMA who could potentially benefit from SPINRAZA, the only life-changing drug therapy available. Notably all patients over 12 years of age and all those who have reached the ability to walk independently are denied treatment."